jRCT2051240289招募中不适用
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 582
- 主要终点
- Progression Free Survival by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ population
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- Female
入选标准
- •Sign and date the tissue prescreening informed consent form (ICF), prior to HER2 central testing. Sign and date the main ICF, prior to the start of any trial- specific qualification procedures. Consent to optional PGx prior to any PGx procedures. For participants in the safety run-in phase, a safety run-in ICF needs to be signed and dated prior to the start of any trial-specific qualification procedures.
- •Adults >=18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is >18 years old.
- •Has histologically confirmed diagnosis of epithelial high-grade ovarian, fallopian tube or primary peritoneal carcinoma (including but not limiting to serous, endometrioid, clear cell, carcinosarcoma, mucinous).
- •Is newly diagnosed FIGO Stage III or IV.
- •Has HER2 expression per 2016 ASCO-CAP gastric cancer IHC scoring (3+/2+/1+) guidelines by prospective central testing. For participants in the safety run-in phase, HER2 expression assessed by either local (require using ASCO-CAP gastric cancer IHC scoring [IHC 3+/2+/1+] guidelines) or central assessment (if available) is acceptable. Submission of the pathology report is required for participants enrolled based on local HER2 IHC results.
- •Has adequate tumor tissue sample available for assessment of HER2 by central laboratory. Tumor tissue block or sufficient tissue slides are required for HER2 testing and retrospective HRD status determination. Participants in the safety run-in phase who are enrolled based on local HER2 IHC results are recommended to provide tumor tissue sample from the same specimen for central assessment.
- •Has a local HRD or breast cancer gene (BRCA) test result available. Participants with BRCA wildtype will have a local HRD test results, as applicable.
- •Has received standard of care bevacizumab in combination with front line platinum based chemotherapy as per approved indication and clinical guidelines and is eligible to continue single agent bevacizumab maintenance per standard of care and investigator discretion.
排除标准
- •Has ovarian, fallopian tube, or peritoneal cancer of non-epithelial origin.
- •Has a BRCA mutation as per local test.
- •Participant to receive PARP inhibitor as maintenance per standard of care and investigator discretion. Reasons for which the participant is not eligible for PARP inhibitor will be recorded in the eCRF as follows: HRD negative, HRD positive with SD as best response after platinum, HRD positive non-serous histology, HRD tested but inconclusive, HRD positive but safety concern (safety concern to be specified).
- •Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug products and other monoclonal antibodies.
- •Previous Cerebral-Vascular Accident, Transient Ischemic Attack or Sub- Arachnoids Hemorrhage within 6 months prior to randomization.
- •Has evidence of bleeding diathesis or significant coagulopathy (in the absence of anticoagulation therapy).
- •Has a history of hemorrhagic disorders, abdominal fistula, gastrointestinal perforation, or active gastrointestinal bleeding within 6 months before randomization.
- •Evidence of active or ongoing bowel obstruction.
- •Has lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within 3 months of the trial randomization, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, pneumonectomy, etc.)
- •Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
- •Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie pulmonary emboli within three months of the trial enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (ie Rheumatoid arthritis, Sjogren's, sarcoidosis etc.), or prior pneumonectomy.
结局指标
主要结局
Progression Free Survival by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ population
时间窗: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
Time from randomization to time of objective radiographic disease progression as assessed by BICR based on RECIST v1.1 or death due to any cause.
次要结局
- Overall Survival in the HER2 IHC 3+/2+ population(From date of randomization to death due to any cause, up to approximately 72 months)
- Progression Free Survival by BICR in the HER2 IHC 3+/2+/1+ population(From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months)
- Overall Survival in the HER2 IHC 3+/2+/1+ population(From date of randomization to death due to any cause, up to approximately 72 months)
- Progression Free Survival by the investigator in HER2 IHC 3+/2+ population(From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months)
- Progression Free Survival by the investigator in HER2 IHC 3+/2+/1+ population(From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months)
研究者
相似试验
尚未招募
不适用
A phase 1B/2 study of trastuzumab, bevacizumab with paclitaxel for HER2-positive gastric cancer in a second-line therapyNeoplasmsKCT0008209Kangbuk Samsung Medical Center47
尚未招募
不适用
Trastuzumab deruxtecan(T-DXd and Afatinib combination in HER2-low advanced gastric cancerKCT0009134Samsung Medical Center61
招募中
1 期
Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing Brain Metastases. (The TUXEDO-4 Study)HER2-low breast cancer presenting with newly diagnosed or progressing brain metastases with or without type II leptomeningeal disease.CTIS2023-506702-39-00Medica Scientia Innovation Research S.L.27
进行中（未招募）
1 期
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Canceron-metastatic HER2-positive Breast CancerMedDRA version: 23.0Level: PTClassification code: 10065430Term: HER2 positive breast cancer Class: 100000004864CTIS2022-501504-95-00Karolinska University Hospital330
进行中（未招募）
1 期
Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain MetastasesHER2-positive Breast Cancer with newly diagnosed or progressing Brain MetastasesEUCTR2020-000981-41-ATMed. Univ. Wien, Klinik f. Innere Mdizin I, Onkologie15